Calliditas Therapeutics (Group)

https://www.calliditas.se

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs. *

	Start	2017-11-15 renamed
	Today	Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
	Predecessor	Pharmalink AB
	Industry	pharmaceutical
	Industry 2	Nefecon®
	Person	Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
	Person 2	Johansson, Fredrik (Pharmalink AB 201708– CFO before Birdstep Technology/Techstep ASA)

	Region	Stockholm
	Country	Sweden
	Street	1 Kungsbron C8
	City	11122 Stockholm
	Tel	+46-8-411-3005
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2020-03-31)
	Currency	SEK
	Annual sales	184,829,000 (net sales, consolidated (2019) 2019-12-31)
	Profit	-32,578,000 (2019-12-31)
	Cash	753,540,000 (2019-12-31)

		* Document for »About Section«: Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics".

		Record changed: 2024-02-12